No spam - just the good stuff

Subscribe to our newsletter

News

Cellular

Biotech Longeveron files for $30M IPO

“Whole-body mitochondrial transfusion” start-up lands funding

It’s time to sit up and take notice of mitochondria

CohBar CEO on the development of a “true portfolio” of mitochondria based therapeutics for the treatment of chronic and age-related diseases.

New Buck Institute study is treasure trove for longevity research

Harvard spin-off Cellvie Inc closes $5M seed round

Clearance of senescent cells for improved cognition

Promising restorative therapy potentially 5 years away

Longevity Escape Velocity within 10 years?

“Adjust the immune system… de-age the brain”

Predicting longevity using polygenic risk scores

CohBar announces preclinical collaboration with NIAID

Protein turnover is correlated to lifespan

New Longevity supplement targets cognitive decline

New Buck Institute research is big news for Longevity

Turn Bio announce worldwide IP for mRNA tech

Gut health shines a light on Longevity

Longevity companies to watch in 2021

A year in Longevity: progress perspectives

A year in Longevity: different perspectives

Joined-up thinking and the hallmarks of aging

Proteostasis as a therapeutic target in age-related neurodegeneration

Autophagy in T cells maintained by spermidine

Simulations open the door to cell aging reversal

Resetting cells to a youthful regenerative state

Viral vector start-up aims to tackle gene therapy Longevity bottleneck

Found: the missing link in the Longevity ‘supply-chain’

A novel approach to aging – epigenetics and cellular variability

Oxidants can slow cell aging

Novel pathway to cracking the Alzheimer’s puzzle

Profiling and understanding plasma proteomes could unlock Longevity

Peptide molecule causes cancer cells to self destruct

Epigenetic regulation of protein homeostasis following DNA damage

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.